B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $8.00. The company’s shares closed last Tuesday at $3.51.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 37.5% and a 58.2% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and NGM Biopharmaceuticals.
Spectrum Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.00, representing a 184.9% upside. In a report issued on February 23, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
The company has a one-year high of $5.24 and a one-year low of $1.74. Currently, Spectrum Pharmaceuticals has an average volume of 2.32M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.